The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Motif Bio takeover called off; Yamana buys at Wasamac

Mon, 14th Jun 2021 20:33

(Alliance News) - The following is a round-up of updates by London-listed companies issued on Monday and not separately reported by Alliance News:

----------

TBC Bank Group PLC - Tbilisi, Georgia-headquartered lender - Says just under 24% of shareholders vote against approval of directors' remuneration report. "The executive remuneration arrangements reported on in the 2020 directors' remuneration report are fully aligned with our directors' remuneration policy, which was approved by 99.9% of our shareholders at our 2018 AGM," lender explains. It continues: "Over the last year, we have engaged with shareholders about executive remuneration in connection with the preparation of the new directors' remuneration policy, which the board notes was approved by 96.2% of shareholders at the AGM. We will continue our active dialogue with shareholders on executive remuneration matters, particularly with those who decided to vote against this resolution, and intend to further consult with shareholders during the coming months to understand their concerns." Also notes 25% of shareholders vote against resolution to disapply statutory pre-emption rights.

----------

Spectra Systems Corp - Rhode Island-based authentication technology provider - Reports lack of quorum at annual general meeting. Notes only 24% of shares voted, which came from 23 ballots.

----------

Cadence Minerals PLC - UK-based mineral resources investor - Says 1% investee Macarthur Minerals o spin-out its non-iron ore assets in the Pilbara into Infinity Mining Ltd. Infinity intends to IPO in Australia. "This strategy will fast track further exploration and the future development potential of the Pilbara Assets and allow Macarthur to focus solely on the development of its flagship iron ore projects situated at Lake Giles in the Yilgarn region of south-western, Western Australia," Macarthur explains.

----------

Braveheart Investment Group PLC - makes strategic investments in companies it thinks will outperform - Notes investee Paraytec's grant funded project to deploy its ActiPix technology in the field of Alzheimer's disease diagnosis is "progressing well". "Prototype instruments are being built, to test blood for protein biomarkers. If successful, these instruments will be used by clinicians aiming to more accurately diagnose patients and monitor their treatment," company adds.

----------

Yamana Gold Inc - gold, silver and copper miner in Canada, Chile, Brazil and Argentina - Agrees to buy the Francoeur, Arntfield and Lac Fortune gold properties adjoining the company's Wasamac project as well as additional claims in the Beuchastel township to the east of the Wasamac project from Globex Mining Enterprises Inc. Will pay CAD4.0 million, about USD3.3 million, in shares to Globex, with remaining CAD11.0 million, payable over 4 years, to be paid in either cash or shares. On top of that, Globex will receive a 2% gross metal royalty from Yamana, of which 0.5% may be bought back at any time by Yamana for CAD1.5 million, following which the royalty would be reduced to a 1.5% gross metal royalty.

----------

Secure Property Development & Investment PLC - eastern Europe focused property investor - Signs three agreements over transfer of certain assets owned by SPDI in Romania and Ukraine to Arcona Property Fund NV. Under the terms of the agreements, SPDI will receive approximately 605,000 new ordinary shares in Arcona and about 145,000 warrants over ordinary shares in Arcona, as well as EUR1 million in cash. Says transaction worth total of EUR8.2 million.

----------

Motif Bio PLC - AIM cash shell - Says BiVictriX Therapeutics Ltd acquisition cancelled after shareholders at annual general meeting vote against several resolutions. As a result, shares will be cancelled from trading on AIM on Tuesday. Has previously proposed name change to BiVictriX Therapeutics and placing and subscription to raise GBP10.1 million via issue of 50.5 million new shares, at a price of 20 pence each. Both of which will now not go ahead.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
24 Oct 2019 10:31

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

UK WINNERS & LOSERS SUMMARY: Woodford Trust Up 30% As Schroders Tapped

Read more
10 Oct 2019 11:52

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Motif Bio Meeting With US FDA Confirms Need For Another iclaprim Trial

Read more
2 Oct 2019 11:59

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Motif Bio To Raise GBP600,000 Via Placing To Fund Major Restructure

Read more
1 Oct 2019 17:09

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Motif Bio To Become Cash Shell If Restructuring Proposals Accepted

Read more
2 Sep 2019 11:39

Motif Bio Delays Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Novel antibiotics-focused biopharmaceutical company Motif Bio PLC said Monday it has agreed with Hercules Capital Inc to postpone the next amortisation date for its loan and date

Read more
19 Aug 2019 10:46

WINNERS & LOSERS SUMMARY: IXICO Rises On Positive Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------J up 3.8%. The is

Read more
19 Aug 2019 09:29

Motif Bio Receives US State Funding For Iclaprim Listeria Study

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said Monday that the US government will fund a study on the effectiveness of the iclaprim drug against listeria monocytogenes.Shares a

Read more
1 Aug 2019 11:43

Motif Bio Postpones Next Amortisation Date Of Hercules Loan Facility

(Alliance News) - Biopharmaceutical firm Motif Bio PLC said on Thursday has amended its loan agreement with Hercules Capital Inc, delaying the next amortisation date by one month to September a to

Read more
12 Jun 2019 18:16

Amphion Innovations To Work With Debt Providers To Refinance Facility

(Alliance News) - Amphion Innovations PLC said Wednesday its debt providers have told the company the excess value of the collateral does not meet the terms of an agreed facility between the in at

Read more
6 Jun 2019 10:47

WINNERS & LOSERS SUMMARY: Rolls Royce And L&G Rise On Pension Pact

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Rolls up

Read more
31 May 2019 15:32

Motif Bio Shareholders Reject Remuneration Report Resolution

LONDON (Alliance News) - Motif Bio PLC on Friday said that shareholders voted against approval of the company's remuneration report.At the clinical-stage biopharmaceutical firm's on

Read more
1 May 2019 10:46

Motif Bio to work with Lamellar on cystic fibrosis treatment possibility

(Sharecast News) - Clinical-stage biopharmaceutical company Motif Bio has signed an agreement with Lamellar Biomedical, under which Motif Bio would conduct an in vivo preclinical study evaluating iclaprim in combination with Lamellar's patented 'Lamellasome' technology.

Read more
1 May 2019 09:26

Motif Bio Shares Up On Agreement With Lamellar To Start Clinical Study

LONDON (Alliance News) - Shares rose in Motif Bio PLC on Wednesday as it signed an agreement with Lamellar Biomedical to study the combination of Motif's iclaprim with Lamellar's in the at

Read more
26 Apr 2019 14:09

Motif Bio Appoints Andrew Powell As Non-Executive Director

LONDON (Alliance News) - Motif Bio PLC, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, said Friday it has appointed Andrew Powell as non-executive has as

Read more
15 Apr 2019 10:50

Motif Bio 2018 Loss Narrows As Research Costs Fall Despite US Delay

LONDON (Alliance News) - Motif Bio PLC said Monday its 2018 loss narrowed significantly as research costs fell, despite an unexpected delay in its new drug application in the US.In 2018, to

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.